Bank of America Reports 5.1% Stake in MacroGenics
Bank of America Corp reported beneficial ownership of 3,258,574 shares of MacroGenics, Inc. common stock, equal to 5.1% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bank of America Corp reported beneficial ownership of 3,258,574 shares of MacroGenics, Inc. common stock, equal to 5.1% of the class. The filing bases its calculation on 63,560,068 outstanding shares as of March 27, 2026.
The statement is a Schedule 13G filed on behalf of Bank of America and certain subsidiaries, listing shared voting and dispositive power over the reported shares. The filing is signed by an authorized signatory on May 14, 2026.
Insights
Bank of America reports a 5.1% passive stake in MacroGenics.
The filing shows 3,258,574 shares beneficially owned with shared voting and dispositive power. The calculation cites March 27, 2026 share totals of 63,560,068, which produces the 5.1% figure.
Because this is a Schedule 13G, the position is presented as passive under the reported classification. Subsequent filings or amendments would disclose any change in voting intent or a shift to active ownership.
Key Figures
Key Terms
Schedule 13G regulatory
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Bank of America hold in MacroGenics (MGNX)?
Does the Schedule 13G indicate active control of MacroGenics?
Which Bank of America entities are included in this filing?
What date does the ownership calculation reference?
When was the Schedule 13G signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.